Medicaid

NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant

NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...

NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant

NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...

New Data at American Foregut Society’s 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo...

error: Content is protected !!